

# Evaluating Pattern and Recurrence Rate of Stage T1 and T2 Endometrial Cancer Treated at a Tertiary Cancer Centre in Pakistan

Sadia Anjum<sup>1</sup>, Sadia Abdullah<sup>1</sup>, Muhammad Anas Tahseen Asar<sup>1</sup>, Esha Khalid<sup>1</sup>, Maria Kousar<sup>1</sup>, Anusha Haider<sup>1</sup>  
<sup>1</sup>Shaukat Khanum Memorial Cancer Hospital and Research Centre, Radiation Oncology, Lahore, Pakistan.

## Introduction

Endometrial cancer is the most common gynecological malignancy. T1–T2 stages usually have favorable prognosis. High-risk histology (serous, clear cell) is linked with higher recurrence. This audit evaluates adherence to NCCN and ESGO/ESTRO guidelines and outcomes.

## OBJECTIVE

- Assess adherence to international guidelines in stage T1–T2 endometrial cancer.
- Identify protocol deviations.
- Evaluate recurrence rate in treated patients.

## METHODS

- Retrospective audit (Jan 2023–Dec 2024)
- Total endometrial cancer patients: 430
- Audit sample: 148 (T1–T2)
- Standard: ≥90% compliance
- Data: Histology, surgery, adjuvant therapy, recurrence


## Results

- 148 patients with T1–T2 disease
- Compliance: 95.3%
- Protocol deviations: 7 (4.7%)
  - Poor histology (1)
  - Fragmented biopsy (1)
  - Dual primaries (1)
  - Hormonal treatment (1)
  - Absconded (3)
- Recurrence: 13 (8%)
- Compliance target of 90% exceeded, showing strong guideline alignment.

## CONCLUSION

High compliance (95.3%) with guidelines achieved. Acceptable recurrence rate (8%). Current protocols effective, no immediate re-audit required. Ongoing monitoring and education essential

Age-Standardized Rate (World) per 100 000, Incidence, Both sexes, in 2022  
Corpus uteri



Popl	Population	ASR (W)
Sing	Afghanistan	5.0
Japa	Azerbaijan	5.0
Arm	Maldives	4.7
Isra	Korea, Democratic Peopl.	4.5
Türk	Sri Lanka	4.3
Geor	Qatar	4.1
Kaza	Pakistan	3.8
Unit	Oman	3.5
Phil	Lao People's Democratic.	3.3
Brur	Cambodia	3.1
Kuw	Iran, Islamic Republic .	3.1
Mal	Myanmar	2.7
Sauc	India	2.5
Bahr	Timor-Leste	2.3
Syri	Mongolia	1.9
Lebe	Bhutan	1.3
Viet	Nepal	1.3
Kore	Bangladesh	1.2
Jord	Yemen	0.15
Gaza Strip and West Ban.		6.9
Kyrgyzstan		6.9
Thailand		6.9
China		6.8
Tajikistan		6.0
Turkmenistan		5.4
Indonesia		5.3
Uzbekistan		5.3
Iraq		5.2

All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Cancer TODAY | IARC  
https://gco.iarc.who.int/today  
Data version: Globocan 2022 (version 1.1) - 08.02.2024  
© All Rights Reserved 2025

International Agency  
for Research on Cancer  
World Health  
Organization